- Home
- DERM vs IPHA Comparison
DERM vs IPHA Comparison
Compare DERM & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- IPHA
- Stock Information
- Founded
- DERM 2014
- IPHA 1999
- Country
- DERM United States
- IPHA France
- Employees
- DERM N/A
- IPHA N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- IPHA Health Care
- Exchange
- DERM Nasdaq
- IPHA Nasdaq
- Market Cap
- DERM 165.6M
- IPHA 160.1M
- IPO Year
- DERM 2021
- IPHA 2019
- Fundamental
- Price
- DERM $7.14
- IPHA $2.08
- Analyst Decision
- DERM Strong Buy
- IPHA Strong Buy
- Analyst Count
- DERM 3
- IPHA 1
- Target Price
- DERM $12.67
- IPHA $11.00
- AVG Volume (30 Days)
- DERM 199.4K
- IPHA 6.7K
- Earning Date
- DERM 08-12-2025
- IPHA 09-17-2025
- Dividend Yield
- DERM N/A
- IPHA N/A
- EPS Growth
- DERM N/A
- IPHA N/A
- EPS
- DERM N/A
- IPHA N/A
- Revenue
- DERM $56,397,000.00
- IPHA $20,831,349.00
- Revenue This Year
- DERM $28.10
- IPHA $350.96
- Revenue Next Year
- DERM $53.84
- IPHA $32.92
- P/E Ratio
- DERM N/A
- IPHA N/A
- Revenue Growth
- DERM N/A
- IPHA N/A
- 52 Week Low
- DERM $3.54
- IPHA $1.29
- 52 Week High
- DERM $8.90
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- DERM 45.80
- IPHA 46.69
- Support Level
- DERM $7.23
- IPHA $2.04
- Resistance Level
- DERM $7.51
- IPHA $2.20
- Average True Range (ATR)
- DERM 0.36
- IPHA 0.09
- MACD
- DERM -0.02
- IPHA -0.02
- Stochastic Oscillator
- DERM 47.83
- IPHA 11.27
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.